AbbVie scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, AbbVie increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. AbbVie forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Allergan is a signatory of the Business Roundtable's 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism over traditional shareholder obligations. Abbvie is a member of the MCCA, indicating its focus on recruiting, retaining, and promoting employees based on race. The company is a Copper sponsor of Out & Equal and is a corporate partner of the NGLCC. AbbVie supports the Equality Act and donated to the Equality PAC. For these reasons, AbbVie receives a High Risk rating.